Loading stock data…
DVA
$198.19+6.11 (+3.18%)
Market ClosedLast close Jun 9
DaVita Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
DaVita Inc. in the Healthcare sector is trading at $198.19 with a market capitalization of $12.5B. Wall Street consensus targets $193.71 (7 analysts), implying a -2.3% move over the next 12 months. The stock is currently near its 52-week high of $202.69, remaining 41.7% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$198.19
Potential Downside
57.4%
Whystock Fair Value$84.45
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Mean target$193.71-2.3%
Range$145.00 – $235.00
Fundamentals
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpa...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.52B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
18.77
Beta
Defensive asset. Lower volatility than the S&P 500.
0.84
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-103.43%
Volume
Today's trading volume
534,194
Recent News
4 Outpatient Home Health Stocks Benefiting From Industry Trends
An aging population and rising telehealth and AI adoption boost demand in the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, LFST and AVAH stand to benefit.
Best Growth Stocks to Buy for June 9th
DVA, XPO, and PBI it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 9, 2026.
Best Value Stocks to Buy for June 9th
THG, DVA and PLOW made it to the Zacks Rank #1 (Strong Buy) value stocks list on June 9, 2026.
FMS and Home Dialysis: How 5008X Could Reset Demand
FMS scales 5008X high-volume HDF and expands home dialysis, aiming for benefits later in 2026 and a bigger payoff in 2027+.
Assessing DaVita (DVA) Valuation After Strong Q1 2026 Beat And Upgraded Guidance
DaVita (DVA) is back in focus after first quarter 2026 revenue and earnings surpassed analysts' expectations, prompting management to lift full year guidance and drawing fresh attention from investors and research desks. See our latest analysis for DaVita. The strong first quarter has come after a powerful run in the stock, with the share price up 27.46% over 90 days and a 67.81% year to date share price return. The 3 year total shareholder return of 97.13% suggests longer term holders have...